New Pharmaceuticals market report from Datamonitor: "Market and Product Forecasts: Asthma - Premium products to offset loss to generics"
Boston, MA -- (SBWIRE) -- 10/24/2012 -- The asthma market has seen strong growth, with increased uptake of relatively expensive combination products. This trend is expected to change in the near future as sales growth will slow, and even turn negative, as key products face generic entry. However, by 2021, Datamonitor forecasts a return to positive growth such that the market will maintain value, with a CAGR over 2012-21 of 0.1%.
- Access Datamonitor's patient-based asthma market forecast for the seven major markets, with transparent methodology and clear assumptions.
- Understand how market dynamics are changing and which drug classes will be most impacted in the next 10 years.
- Gain insight into how late-stage pipeline products will change the market and which currently marketed products are insulated against brand erosion.
- See how generics will impact the asthma market and gain insight into which drug classes are the most vulnerable.
View Full Report Details and Table of Contents
Datamonitor forecasts four new product launches in asthma over the next 10 years. New products for asthma across the seven major markets will counteract generic erosion and help the market to maintain value. Datamonitor forecasts the asthma market to increase from $15.0bn in 2012 to $15.1bn by 2021, representing a 2012-21 CAGR of 0.1%.
The impact of generics will vary considerably by drug class. The antileukotriene class is expected to see a rapid decline as Singulair succumbs to generic entry. However, Datamonitor expects a relatively low impact of generics on inhaled combination products, although price discounting and patient switching will vary by country.
While the ICS/LABA class will remain unrivalled as the most profitable in asthma, it will see significant changes. The first ICS/LABA generics are expected to enter the market from 2013. However, greater patient switching is expected from current market leaders to the first once-daily ICS/LABAs, than to generics.
Reasons to Get this Report
- How can generics compete with new product launches in the ICS/LABA class?
- How will current market leaders be impacted by additional product launches and which products will resist brand erosion?
- How are class dynamics changing in asthma and which drug classes will be the most profitable in 2021?
- How do asthma markets differ across the seven major markets and how will these markets react to events over the next 10 years?
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries
- Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution
- Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
- Market and Product Forecasts: Asthma in China - Market set to fragment as novel therapies launch
- Asthma Market Forecast
- Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
- Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Life Insurance in India, Key Trends and Opportunities to 2015
- Life Insurance in Brazil, Key Trends and Opportunities to 2015
- Life Insurance in China, Key Trends and Opportunities till 2015
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)